Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate

@article{Stamey1987ProstateSpecificAA,
  title={Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate},
  author={T. Stamey and N. Yang and A. Hay and J. McNeal and F. Freiha and E. Redwine},
  journal={The New England Journal of Medicine},
  year={1987},
  volume={317},
  pages={909-916}
}
To compare the clinical usefulness of the serum markers prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP), we measured them by radioimmunoassay in 2200 serum samples from 699 patients, 378 of whom had prostatic cancer. PSA was elevated in 122 of 127 patients with newly diagnosed, untreated prostatic cancer, including 7 of 12 patients with unsuspected early disease and all of 115 with more advanced disease. The PSA level increased with advancing clinical stage and was… Expand

Paper Mentions

Interventional Clinical Trial
Current standard prostate biopsy techniques, used to definitively diagnose prostate cancer (PC), utilises an ultrasound guided biopsy approach, that offers unsatisfactory specificity… Expand
ConditionsProstate Cancer
InterventionDiagnostic Test
Interventional Clinical Trial
In this open randomized controlled trial, we seek to study whether prostate cancer screening using multiparametric prostate magnetic resonance imaging (mpMRI) improves the detection… Expand
ConditionsProstate Cancer
InterventionDevice, Other
Prostate-specific antigen as a marker of adenocarcinoma of prostate
TLDR
It is suggested that PSA is more sensitive than PAP in local and advanced prostatic cancer and may be more useful in monitoring responses and recurrence after therapy. Expand
Relative value of prostate-specific antigen and prostatic acid phosphatase in diagnosis and management of adenocarcinoma of prostate. Ohio State University experience.
TLDR
The data indicate that PSA is a more sensitive but less specific tumor marker than PAP in the detection of prostate cancer and PSA appears to be more sensitive than P AP in monitoring the response to treatment. Expand
Prostate specific antigen--a screening test for prostatic cancer?
TLDR
The use of PSA as a screening test in a group of patients with prostatism appears justified, but with a positive predictive value of only 47%, its use in a mass unselected screening programme is not recommended. Expand
Prostate-specific antigen testing in untreated and treated prostatic adenocarcinoma.
TLDR
Routine use of PSA testing as a mass screening modality for prostatic cancer has not been considered cost-effective and patients with a persistently elevated PSA level for more than 6 months postoperatively should be assessed for residual or recurrent local or systemic disease. Expand
Prostate specific antigen and prostatic acid phosphatase for monitoring therapy of carcinoma of the prostate.
TLDR
Serial serum prostatic acid phosphatase (PAP) and prostate specific antigen (PSA) measurements are performed in 871 patients treated with hormonal combination therapy for stage C and D prostate cancer patients treated by combination endocrine therapy and they show that serum PSA measurements are superior to those of serum PAP for predicting disease recurrence. Expand
Screening for prostatic carcinoma with prostate specific antigen.
TLDR
It is concluded that PSA represents an important adjunct to digital rectal examination for the early detection of prostatic carcinoma and the efficacy of this or any other early detection test to decrease prostate cancer mortality necessitates the results of prospectively randomized clinical trials. Expand
Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients.
TLDR
Serum prostate specific antigen was significantly decreased by transurethral resection of prostatic tissue in patients with cancer, as has been shown previously in Patients with benign prostatic hyperplasia. Expand
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer.
TLDR
The combination of measurement of the serum PSA concentration and rectal examination, with ultrasonography performed in patients with abnormal findings, provides a better method of detecting prostate cancer thanrectal examination alone. Expand
Serum prostate-specific antigen levels in stage A1 prostatic cancer.
TLDR
Elevation of PSA levels caused by CAP is indicative of a tumor burden greater than that found in stage A1 CAP, in the authors' experience. Expand
Percent free prostate-specific antigen: entering a new era in the detection of prostate cancer.
TLDR
Deciding percent free PSA enhances the ability of PSA testing to distinguish between prostate cancer and benign prostatic hyperplasia, and can substantially improve the clinical utility of the PSA test for detecting early, curable prostate cancer. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 15 REFERENCES
Evaluation of prostate-specific antigen and prostatic acid phosphatase as prostate cancer markers.
TLDR
The data suggest PSA is a sensitive useful tumor marker for the diagnosis and management of prostate cancer, and PAP, in combination with PSA, may serve as a useful adjunct for differential diagnosis and confirmation of advanced stage prostate cancer. Expand
Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer.
TLDR
PA may be a useful adjuvant marker for monitoring tumor growth in patients with regionally confined prostate cancer and once a PA level of 88 ng/ml was reached, there was an average time of less than 2 months before a recurrence was clinically confirmed. Expand
Immunocytochemical localisation of prostate-specific antigen: specificity and application to clinical practice.
TLDR
An immunocytochemical method to localise prostate-specific antigen (PSA) in paraffin sections was used to establish the prostatic origin of both primary and metastatic tumours, finding 11 patients with neoplasms of the base and neck of the bladder that could not be categorised as prostatic or urothelial in origin by clinical and endoscopic assessment or by conventional histopathology. Expand
Carcinoma of the Prostate with Atypical Immunohistological Features: Clinical and Histologic Correlates
TLDR
In seven patients with undifferentiated carcinoma of the prostate, the immunohistochemical stain for prostatespecific antigen was negative, and prostatic carcinoma with this histologic pattern frequently loses prostate- specific antigen immunoreactivity. Expand
Immunochemical evaluation of the organ specificity of prostatic acid phosphatase.
TLDR
In a survey of normal and cancerous human tissues, it is proposed that this material is from serum (low concentrations of immunoreactive prostatic acid phosphatase are present in the serum of men and women) and that it is excreted into urine by the kidneys. Expand
Serum prostatic antigen measurement in localized prostatic cancer: correlation with clinical course.
TLDR
It appears that serum prostatic antigen is a good indicator and predictor of the development of distant metastasis in this group of patients treated for localized prostatic carcinoma. Expand
Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay.
TLDR
Results indicate that PA is a histiotypic product of the prostate and may be of use as an adjunctive tool in diagnostic procedures of prostate cancer. Expand
Measurement of prostate-specific antigen by radioimmunoassay.
TLDR
Sequential measurement of both tissue markers in specimens from several patients who were undergoing therapy for prostate cancer appeared to provide supplemental information regarding treatment success, as established by assay of specimens from 276 apparently normal men. Expand
Immunohistochemical identification of prostatic acid phosphatase: correlation of tumor grade with acid phosphatase distribution.
TLDR
A correlation of the PSAP staining with the degree of differentiation and the ability of the tumor to form a gland was observed: more intense and uniform staining in well differentiated tumors and less intense and more variable stains in poorly differentiated tumors. Expand
PATTERNS OF PROGRESSION IN PROSTATE CANCER
TLDR
It was concluded that the natural history of prostate cancer is highly predictable and the capacity to metastasise probably develops only in tumours which have grown much larger than 1 ml and acquired poorly differentiated areas as a manifestation of the phenomenon of tumour progression. Expand
...
1
2
...